Low-molecular-weight heparin for the long-term treatment of symptomatic venous thromboembolism: Meta-analysis of the randomized comparisons with oral anticoagulants

Journal of Thrombosis and Haemostasis

Volumn 1, Issue 9, 2003, Pages 1906-1913

  Iorio, A ^a   Guercini, F ^a   Pini, M ^b  

^a UNIVERSITY OF PERUGIA   (Italy)

^b Ospedale di Fidenza   (Italy)

Author keywords

Long term treatment; Low molecular weight heparin; Oral anticoagulants; Venous thromboembolism

Indexed keywords

ANTICOAGULANT AGENT; LOW MOLECULAR WEIGHT HEPARIN;

ARTICLE; BLEEDING; CHEMICALLY INDUCED DISORDER; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; HUMAN; META ANALYSIS; MORTALITY; NEOPLASM; RANDOMIZED CONTROLLED TRIAL; RECURRENT DISEASE; STATISTICS; THROMBOEMBOLISM; TREATMENT OUTCOME; VEIN THROMBOSIS;

ANTICOAGULANTS; HEMORRHAGE; HEPARIN, LOW-MOLECULAR-WEIGHT; HUMANS; NEOPLASMS; RANDOMIZED CONTROLLED TRIALS; RECURRENCE; THROMBOEMBOLISM; TREATMENT OUTCOME; VENOUS THROMBOSIS;

EID: 2442448579     PISSN: 15387933     EISSN: 15387836     Source Type: Journal    
DOI: 10.1046/j.1538-7836.2003.00364.x     Document Type: Article

References (32)

1. Koopman MM, Prandoni P, Piovella P, Ockelford PA, Brandjes DP, van der Meer J, Gallus AS, Simonneau G, Chesterman CH, Prins MH. Treatment of venous thrombosis with intravenous unfractionated he-parin administered in the hospital as compared with subcutaneous low-molecular-weight heparin administered at home. The Tasman Study Group. N Engl J Med 1996; 334: 682-7.
2. Hull RD, Raskob GE, Brant RF, Pineo GF, Valentin KA. The importance of initial heparin treatment on long-term clinical outcomes of anti-thrombotic therapy. The emerging theme of delayed recurrence. Arch Inter Med 1997; 157: 2317-21.
3. Ginsberg JS, Hirsh J. Treatment of venous thromboembolism.In: Col-man RW, Hirsh J, Marder VJ, Clowes AW, George JN, eds. Hemostasis and Thrombosis. Basic Principles and Clinical Practice. Philadelphia: Lippincott Williams, Wilkins, 2000: 1405-12.
4. Hyers TM, Hull RD, Morris TA, Tapson V. Antithrombotic therapy for venous thromboembolic disease. Sixth ACCP Consensus Conference on Antithrombotic Therapy. Chest 2001; 119: 176S-193S.
5. Hutten BA, Lensing AW, Kraaijenhagen RA, Prins MH. Safety of treatment with oral anticoagulants in the elderly. A systematic review. Drugs Aging 1999; 14: 303-12.
6. Levine MN, Raskob G, Landefeld S, Kearon K. Hemorrhagic compli cations of anticoagulant treatment. Sixth ACCP Consensus Conference on Antithrombotic Therapy. Chest 2001; 119: 108S-121S.
7. Palareti G, Manotti C, D'Angelo A, Pengo V, Erba N, Moia M, Ciavarella N, Devoto G, Berrettini M, Leali N, Poggi M, Legnani C, Musolesi S, Coccheri S. Thrombotic events during oral anticoagulant treatment, results of the inception-cohort, prospective, collaborative ISCOAT study: ISCOAT Study Group. Italian Study on Complications of Oral Anticoagulant Therapy. Thromb Haemost 1997; 78: 1438-43.
8. Hull R, Delmore T, Genton E, Hirsch J, Gent M, Sackett D, McLoughlin D, Armstrong P. Warfarin sodium versus low-dose heparin in the long-term treatment of venous thrombosis. N Engl J Med 1979; 301: 855-8.
9. Hull R, Delmore T, Carter C, Hirsh J, Genton E, Gent M, Turpie G, McLaughlin D. Adjusted subcutaneous heparin versus warfarin sodium in the long-term treatment of venous thrombosis. N Engl J Med 1982; 306: 189-94.
10. Levine M, Gent M, Hirsh J, Ledere J, Anderson D, Weitz J, Ginsberg J, Turpie AG, Demers C, Kovacs M. A comparison of low-molecular-weight heparin administered primarily at home with unfractionated heparin administered in the hospital for proximal deep-vein thrombosis. N Engl J Med 1996; 334: 677-81.
11. Levine MN, Hirsh J, Horsewood P, Roberts RS, Gent M, Kelton JG. Heparin-induced thrombocytopenia in patients treated with low-mole cular-weight heparin or unfractionated heparin. N Engl J Med 1995; 332: 1330-5.
12. Monreal M, Lafoz E, Olive A, del Rio L, Vedia C. Comparison of subcutaneous unfractionated heparin with a low molecular weight heparin (Fragmin) in patients with venous thromboembolism and contraindications to coumarin. Thromb Haemost 1994; 71: 7-11.
13. Mantel N, Haenszel W. Statistical aspects of the analysis of data from retrospective studies of disease. JNatl Cancer Inst 1959; 22:719-48.
14. Collins R, Gray R, Godwin J, Peto R. Avoidance of large biases and large random errors in the assessment of moderate treatment effects: the need for systematic overviews. Statistics Med 1987; 6: 245-54.
15. Altman DG. Practical Statistics for Medical Research. London: Chap man & Hall, 1991.
16. Pini M, Aiello S, Manotti C, Pattacini C, Quintavalla R, Poli T, Tagliaferri A, Dettori AG. Low molecular weight heparin versus warfarin in the prevention of recurrences after deep vein thrombosis. Thromb Haemost 1994; 72: 191-7.
17. Das SK, Cohen AT, Edmondson RA, Melissari E, Kakkar VV. Low-molecular-weight heparin versus warfarin for prevention of recurrent venous thromboembolism: a randomized trial. World J Surg 1996; 20: 521-6.
18. Gonzalez-Fajardo JA, Arreba E, Castrodeza J, Perez JL, Fernandez L, Agundez I, Mateo AM, Carrera S, Gutierrez V, Vaquero C. Venographic comparison of subcutaneous low-molecular-weight heparin with oral anticoagulant therapy in the long-term treatment of deep venous thrombosis. J Vase Surg 1999; 30: 283-90.
19. Lopaciuk S, Bielska-Falda H, Noszczyk W, Bielawiec M, Witkiewicz W, Filipecki S, Michalak J, Ciesielski L, Mackiewicz Z, Czestochowska E, Zawilska K, Cencora A. Low molecular weight heparin versus acenocoumarol in the secondary prophylaxis of deep vein thrombosis. Thromb Haemost 1999; 81: 26-31.
20. Veiga F, Escriba A, Maluenda MP, Lopez Rubio M, Margalet I, Lezana A, Gallego J, Ribera JM. Low-molecular weight heparin (Enoxaparin) versus oral anticoagulant therapy (Acenocumarol) in the long-term treatment of deep venous thrombosis in the elderly: a randomized trial. Thromb Haemost 2000; 84: 559-64.
21. Lopez-Beret P, Orgaz A, Fontcuberta J, Doblas M, Martinez A, Lozano G, Romero A. Low-molecular weight heparin versus oral anticoagulant in the long-term treatment of deep venous thrombosis. J Vase Surg 2001; 33: 77-90.
22. Hull R, Pineo G, Mah A, Brant R. The LITE Investigators. Long-term low molecular weight heparin treatment versus oral anticoagulant therapy for proximal deep vein thrombosis. Blood 2000; 96: 1933 (Abstract).
23. Hamann H. Sekundarprophylaxe nach tiefer venenthrombose. Nieder-molekulares Heparin versus Cumarin [Low molecular weight heparin versus coumarin in the prevention of recurrence after deep vein thrombosis]. Zentralblatt Fur Chinirgie 1999; 124: 24-6.
24. Kakkar VV. Dalteparin in the prevention of recurrent dvt - a study vs. warfarin. In: Haemostasis 1994; 24: 45.
25. Kearon C, Gent M, Hirsh J, Weitz J, Kovacs M, Anderson DR, Turpie AG, Green D, Ginsberg JS, Wells P, MacKinnon B, Julian JA. A comparison of three months of anticoagulation with extended anti-coagulation for a first episode of idiopathic venous thromboembolism. N EnglJ Med 1999; 340: 901-7.
26. Agnelli G, Prandoni P, Santamaria MG, Bagatella P, Iorio A, Bazzan M, Moia M, Guazzaloca G, Bertoldi A, Tornasi C, Scannapieco G, Ageno W; Warfarin Optimal Duration Italian Trial Investigators. Three months versus one year of oral anticoagulant therapy for idiopathic deep venous thrombosis. N EnglJ Med 2001; 345: 165-9.
27. PinedeL, Ninet J, Duhaut P, Chabaud S, Demolombe-Rague S, Durieu I, Nony P, Sanson C, Boissel JP; Investigators of the "Duree Optimale du Traitement AntiVitamines K" (DOTAVK) Study. Comparison of 3 and 6 months of oral anticoagulant therapy after a first episode of proximal deep vein thrombosis or pulmonary embolism and comparison of 6 and 12 weeks of therapy after isolated calf deep vein thrombosis. Circula tion 2001; 103: 2453-60.
28. Levine MN, Hirsh J, Gent M. Optimal duration of oral anticoagulant therapy: a randomised trial comparing four weeks with three months of warfarin in patients with proximal deep vein thrombosis. Thromb Haemost 1995; 74: 606-11.
29. Hettiarachchi RJK, Smorenburg SM, Redekop WK, Prins MH, Lensing AWA, Büller HR. Low-molecular-weight heparin treatment and reduced mortality in cancer patients with venous thromboembolism: a meta-analysis. Thromb Haemost 1999; 82: 947-52.
30. Gould MK, Dembitzer AD, Doyle RL, Hastie TJ, Garber AM. Low-molecular-weight heparins compared with unfractionated heparin for treatment of acute deep venous thrombosis. A meta-analysis of rando mized, controlled trials. Ann Intern Med 1999; 130: 800-9.
31. Siragusa S, Cosmi B, Piovella F, Hirsh J, Ginsberg JS. Low-molecular-weight heparins and unfractionated heparin in the treatment of patients with acute venous thromboembolism: results of a meta-analysis. Am J Med; 1995; 100: 269-76.
32. Van der Heijden JF, Hutten BA, Buller HR, Prins MH. Vitamin K antagonists or low-molecular-weight heparin for the long term treatment of symptomatic venous thromboembolism. Cochrane Database Syst Rev; The Cochrane Library, Issue 3. Oxford: Update Software, 2002.